The safety and effectiveness of both RMC-6236 and RMC-6291 KRAS inhibitors are evaluated in a phase Ib/II clinical trial in combination with pembrolizumab (anti-PD-1 antibody) and optionally with chemotherapeutics in NSCLC and other KRAS G12C-positive tumors, respectively (NCT06162221). Here, KRAS is linked to non-small cell lung carcinoma.